Interim report Q1 2021

Seinäjoki, Finland, May 18th, 2021 - Eevia releases an adjusted Interim Report for Q1-21 and makes plans to list its shares in Sweden. After a shareholders' decision on April 21st, Eevia Health Oy has changed its legal form from a private limited company to a public limited company and became Eevia Health Oyj. In the same decision the share capital was increased to EUR 80.000, which followed a pre-IPO equity issue of EUR 1,2 million completed in January 2021.

Eevia Health Oyj is a Finnish producer of organic-certified plant extracts. The company is experiencing rapid growth and to finance needed capacity expansion, the company is preparing an Initial Public Offering (IPO). The IPO will be followed by listing for public trading of its shares at an MTF-exchange in Stockholm.

"For Eevia Health Oyj to be able to compete properly in a EUR 500 billion international nutraceuticals market, we need access to capital to meet the strong demand with more capacity" states CEO, Stein Ulve from Eevia Health Oyj.

Click here to download the report.

Kim Nurmi-Aro, CFO
Eevia Health Oyj
Mobile: +358 50 444 0717
Email: [email protected]

ABOUT EEVIA HEALTH OYJ

Eevia Health Oyj, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant material from the pristine Finnish forests near the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. The focus is on ingredients that protect human health prophylactically, meaning they work to reduce the risk of deteriorating health or even developing a disease. In its portfolio, Eevia Health has immune-modulating products that have effects on Th1-type cytokines, such as IFN- and TNF-α cell signaling molecules, which are very important in the immune response to pathogens (virus, bacteria). Similarly, Eevia Health is developing a new product that prevents protein accumulation in the RPE-cells in the Retina, which may reduce the risk of developing eye disease AMD (Age-Related Macular Degeneration).

Eevia Health is a small, but fast-growing Finnish manufacturer of 100% organically certified plant extracts. Most of its raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion. The safe and effective ingredients of high quality, such as high concentrate bilberry anthocyanin extracts (36%) and pine bark extracts (70% oligomeric proanthocyanidins), are organically certified. Eevia Health operates a modern green-chemistry production facility in Finland, located close to the raw materials. The short value-chain enables an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth.

Nerladdningsbara filer

Interim report Q3 2022


Interim report Q2 2022


Annual report 2021


Auditor's report 2021


Interim report Q1 2022


Year-end report 2021


Interim Report Q3 2021


Interim report Q2 2021


Interim report Q1 2021


Bokslutskommuniké 2020


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
102 45 Stockholm

08-692 21 90

Om beQuoted